Originally published as JCO Early Release 10.1200/JCO.2004.00.1297 on November 21 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harlan, L. C. Articles by Brown, M. L. Search for Related Content PubMed PubMed Citation Articles by Harlan, L. C. Articles by Brown, M. L. Related Articles Related Editorial

Insurance Status and the Use of Guideline Therapy in the Treatment of Selected Cancers

From the Division of Cancer Control and Population Sciences; Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda; and Information Management Services, Silver Spring, MD.

Address reprint requests to Linda C. Harlan, PhD, National Cancer Institute/Applied Research Program, Executive Plaza North Rm 4005, 6130 Executive Blvd MSC 7344, Bethesda, MD 20892-7344; e-mail: lh50w{at}nih.gov

PURPOSE: This study estimates the impact of type of insurance coverage on the receipt of guideline therapy in a population-based sample of cancer patients treated in the community.

PATIENTS AND METHODS: Patients (n = 7,134) from the National Cancer Institute's Patterns of Care studies who were newly diagnosed with 11 different types of cancer were analyzed. The definition of guideline therapy was based on the National Comprehensive Cancer Network treatment recommendations. Insurance status was categorized as a mutually exclusive hierarchical variable (no insurance, any private insurance, any Medicaid, Medicare only, and all other). Multivariate analyses were used to examine the association between insurance and receipt of guideline therapy.

RESULTS: Adjusting for clinical and nonclinical variables, insurance status was a modest, although statistically significant, determinant of receipt of guideline therapy, with 65% of the privately insured patients receiving recommended therapy compared with 60% of patients with Medicaid. Seventy percent of the uninsured patients received guideline therapy, which was nonsignificantly different compared with private insurance. When stratified by race, insurance was a statistically significant predictor of the receipt of guideline therapy only for non-Hispanic blacks.

CONCLUSION: Overall, levels of guideline treatment were lower than expected and particularly low for patients with Medicaid or Medicare only. The use of guideline therapy for ovarian and cervical cancer patients and for patients with rectal cancers was unrelated to type of insurance. Of particular concern is the significantly lower use of guideline therapy for non-Hispanic black patients with Medicaid. After adjusting for other factors, only half of these patients received guideline therapy.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

Related Editorial

• Using Practice Guidelines to Assess Cancer Care Quality
  Peter B. Bach
  JCO 2005 23: 9041-9043 [Full Text]

This article has been cited by other articles:

				E. Ward, M. Halpern, N. Schrag, V. Cokkinides, C. DeSantis, P. Bandi, R. Siegel, A. Stewart, and A. Jemal Association of Insurance with Cancer Care Utilization and Outcomes CA Cancer J Clin, January 1, 2008; 58(1): 9 - 31. [Abstract] [Full Text] [PDF]

				J. R. Lange and C. M. Balch Melanoma in Older Patients ASCO Educational Book, January 1, 2008; 2008(1): 399 - 402. [Abstract] [Full Text] [PDF]

				S. Martin, C. Ulrich, M. Munsell, S. Taylor, G. Lange, and A. Bleyer Delays in Cancer Diagnosis in Underinsured Young Adults and Older Adolescents Oncologist, July 1, 2007; 12(7): 816 - 824. [Abstract] [Full Text] [PDF]

				J. J. Griggs, E. Culakova, M. E.S. Sorbero, M. S. Poniewierski, D. A. Wolff, J. Crawford, D. C. Dale, and G. H. Lyman Social and Racial Differences in Selection of Breast Cancer Adjuvant Chemotherapy Regimens J. Clin. Oncol., June 20, 2007; 25(18): 2522 - 2527. [Abstract] [Full Text] [PDF]

				J. J. Griggs, E. Culakova, M. E.S. Sorbero, M. van Ryn, M. S. Poniewierski, D. A. Wolff, J. Crawford, D. C. Dale, and G. H. Lyman Effect of Patient Socioeconomic Status and Body Mass Index on the Quality of Breast Cancer Adjuvant Chemotherapy J. Clin. Oncol., January 20, 2007; 25(3): 277 - 284. [Abstract] [Full Text] [PDF]

				J. R. Adams, C. Angelotta, and C. L. Bennett When the Risk of Febrile Neutropenia Is 20%, Prophylactic Colony-Stimulating Factor Use Is Clinically Effective, but Is It Cost-Effective? J. Clin. Oncol., July 1, 2006; 24(19): 2975 - 2977. [Full Text] [PDF]